We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

Back to rankings

127 hedge funds and large institutions have $415M invested in Achillion Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 41 increasing their positions, 38 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,106% more call options, than puts

Call options by funds: $3.12M | Put options by funds: $259K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

27% more capital invested

Capital invested by funds: $327M → $415M (+$88.7M)

8% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 38

15% less funds holding

Funds holding: 149 → 127 (-22)

53% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 36

Holders
127
Holders Change
-22
Holders Change %
-14.77%
% of All Funds
2.91%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
17
Increased
41
Reduced
38
Closed
36
Calls
$3.12M
Puts
$259K
Net Calls
+$2.87M
Net Calls Change
+$2.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$15.2M
2
AC
Armistice Capital
New York
+$14.1M
3
GPP
Great Point Partners
Connecticut
+$12.1M
4
Goldman Sachs
Goldman Sachs
New York
+$8.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$7M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$23.5M
2
Morgan Stanley
Morgan Stanley
New York
-$14.7M
3
SCM
Sarissa Capital Management
Connecticut
-$6.55M
4
BI
BVF Inc
California
-$4.63M
5
Renaissance Technologies
Renaissance Technologies
New York
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
CMBA
101
C.M. Bidwell & Associates
Hawaii
$77K +$68.2K +20,825 New
USAA
102
United Services Automobile Association
Texas
$70K +$61.4K +18,775 New
AB
103
Amalgamated Bank
New York
$67K +$7.04K +2,152 +14%
FWM
104
Frontier Wealth Management
Missouri
$58K +$1.64K +500 +3%
IG
105
ING Group
Netherlands
$57K – – –
HighTower Advisors
106
HighTower Advisors
Illinois
$53K +$3.59K +1,098 +8%
JG
107
Jefferies Group
New York
$52K +$45.8K +14,000 New
Prudential Financial
108
Prudential Financial
New Jersey
$48K +$5.56K +1,700 +15%
SG Americas Securities
109
SG Americas Securities
New York
$45K +$3.39K +1,035 +9%
MC
110
Matisse Capital
Oregon
$42K -$406K -124,130 -92%
AIP
111
Ameritas Investment Partners
Nebraska
$38K – – –
TA
112
Teton Advisors
New York
$37K +$32.7K +10,000 New
Canada Life
113
Canada Life
Manitoba, Canada
$32K – – –
NIT
114
NumerixS Investment Technologies
British Columbia, Canada
$29K -$116K -35,300 -82%
LTFS
115
Ladenburg Thalmann Financial Services
Florida
$11K -$1.31K -400 -12%
Zurich Cantonal Bank
116
Zurich Cantonal Bank
Switzerland
$11K – – –
GT
117
Glenmede Trust
Pennsylvania
$5K – – –
MAM
118
Meeder Asset Management
Ohio
$5K +$380 +116 +10%
FANJ
119
Financial Architects (New Jersey)
New Jersey
$4K – – –
RCAG
120
Rehmann Capital Advisory Group
Michigan
$4K +$3.63K +1,109 New
FDCDDQ
121
Federation des caisses Desjardins du Quebec
Quebec, Canada
$3.34K – – –
Daiwa Securities Group
122
Daiwa Securities Group
Japan
$3K +$2.49K +762 New
KF
123
Krilogy Financial
Missouri
$2K – – –
APP
124
Avantax Planning Partners
Iowa
$1K +$1.08K +329 New
O
125
OrbiMed
New York
– -$23.5M -8,170,973 Closed
3 4
5
6 7

ACHN Hedge Fund Activity: Q1 2018 in Review

127 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q1 2018, worth a combined $415M — up 27% from $327M a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of ACHN and 17 opened new positions — a net loss of 19 holders — while 38 trimmed existing stakes and 41 added.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $15.2M. The largest seller was OrbiMed, exiting entirely with an estimated $23.5M sold.

  • 127 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q1 2018, down from 149 in Q4 2017.
  • Funds reported $415M of Achillion Pharmaceuticals stock for Q1 2018, up 27% quarter-over-quarter.
  • 17 funds opened new Achillion Pharmaceuticals positions in Q1 2018 and 36 closed out, a net change of -19 holders.
  • The largest Achillion Pharmaceuticals buyer in Q1 2018 was T. Rowe Price Associates, an estimated $15.2M added.
  • The largest Achillion Pharmaceuticals seller in Q1 2018 was OrbiMed, an estimated $23.5M sold.

Based on aggregated 13F filings for Q1 2018.